Multiple Sclerosis (Relapsing-Remitting) | Decision Base | US | 2015
For Neurologists and Payers, What Opportunities Still Exist for Novel Disease-Modifying Therapies in an Increasingly Crowded Market?
The relapsing-remitting multiple sclerosis (RR-MS) therapy market continues to be developmentally active and commercially compelling, even with the steady increase in the number of approved disease-modifying therapies (DMTs) in recent years. Drug-treatment rates for RR-MS are high, despite a small diagnosed prevalent population relative to many other neurological indications, and neurologists emphasize early treatment intervention to improve long-term outcomes in this chronic disease. Given that the MS disease course is heterogeneous and unpredictable, substantial opportunity remains for more-effective, safer, more-tolerable, and less-burdensome treatment alternatives.
